Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [21] Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
    Zhao, Yongqiang
    Hu, Yu
    Jin, Jie
    Zhao, Xielan
    Wang, Xuefeng
    Wu, Runhui
    Wu, Depei
    Yang, Renchi
    Yang, Feng'e
    Hu, Qun
    Wang, Juan
    Fang, Hai
    Engl, Werner
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [22] Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
    Christiane Dobbelstein
    Georgios Leandros Moschovakis
    Andreas Tiede
    Annals of Hematology, 2020, 99 : 2105 - 2112
  • [23] Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
    Lissitchkov, Toshko
    Willemze, Annemieke
    Jan, Christelle
    Zilberstein, Moshe
    Katragadda, Suresh
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (04)
  • [24] Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study
    Zhao, Liang
    Yang, Hongbin
    Li, Yaochun
    Wang, Zhongqing
    Zhou, Li
    Zhao, Xielan
    Peng, Jie
    HEMATOLOGY, 2022, 27 (01) : 80 - 87
  • [25] Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
    Han, Jeong Pil
    Song, Dong Woo
    Lee, Jeong Hyeon
    Lee, Geon Seong
    Yeom, Su Cheong
    BIOLOGY-BASEL, 2021, 10 (08):
  • [26] Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels
    Zavala, Erendira Pacheco
    Rangel, Juan Sebastian Flores
    Avila, Luis Alexis Ramirez
    Vazquez, Marcos Javier Romero
    Sanchez, Veronica Zendejas
    Oliva, Carlos Vargas
    Villegas, Octavio Martinez
    Medina, Lauro Fabian Amador
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025,
  • [27] Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
    Oldenburg, Johannes
    Chambost, Herve
    Liu, Hai
    Hawes, Charles
    You, Xiaojun
    Yang, Xinqun
    Newman, Vanessa
    Robinson, Tara M.
    Hatswell, Anthony J.
    Hinds, David
    Santos, Sandra
    Ozelo, Margareth
    ADVANCES IN THERAPY, 2024, 41 (06) : 2267 - 2281
  • [28] Inversions of the factor VIII gene in Japanese patients with severe hemophilia A
    Fukuda, K
    Naka, H
    Morichika, S
    Shibata, M
    Tanaka, I
    Shima, M
    Yoshioka, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (03) : 303 - 306
  • [29] Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
    Megias-Vericat, Juan Eduardo
    Bonanad, Santiago
    Haya, Saturnino
    Cid, Ana Rosa
    Marques, Maria Remedios
    Ferrada, Alejandra
    Monte-Boquet, Emilio
    Perez-Alenda, Sofia
    Bosch, Pau
    Querol-Giner, Felipe
    Poveda, Jose Luis
    THROMBOSIS RESEARCH, 2021, 205 : 99 - 105
  • [30] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    Chur-Woo You
    Hee-Sook Son
    Hee Jin Kim
    Eui-Jeon Woo
    Soon-Ae Kim
    Haing-Woon Baik
    International Journal of Hematology, 2010, 91 : 784 - 791